Multi-cancer risk prediction in asymptomatic adults using urinary glycosaminoglycan profiling.
A urine test identifies people at very high cancer risk years before symptoms appear, potentially catching half of cancers earlier when treatment is most effective.
A case-cohort study of 5,436 asymptomatic Dutch adults from the Lifelines Cohort showed that urinary glycosaminoglycan profiles (GAGomes) predict multi-cancer risk over five years, accounting for 36% of variance and stratifying individuals from 0.18% to 32% five-year risk. Screening those in the High GAGome risk group would detect 54% of incident cancers at a 17% false-positive rate, capturing individuals not currently identified by standard age- or smoking-based screening guidelines.
What the study was
- Study design
- case_cohort
- Category
- early_cancer_detection_liquid_biopsy
- Maturity
- Validated
- Journal
- Cancer Epidemiology, Biomarkers and Prevention
Why it surfaced
Novel non-invasive multi-cancer biomarker from urine validated in a large population cohort; potential to expand cancer screening beyond current guideline-defined risk groups; published in Cancer Epidemiology, Biomarkers and Prevention.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.